Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

Wenyuan Xiong, Rainer Strotmann, Joakim Nyberg et al.|Cancer Chemotherapy and Pharmacology|2022

Cited by 12